Compare McKesson Corporation (MCK) vs Opendoor Technologies Inc (OPEN) Price & Performance

McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.

The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.

Opendoor Technologies (OPEN) trades at $2.27 with no recent price movement, reflecting ongoing investor caution. The stock shows bearish technical signals with most moving averages and oscillators indicating selling pressure. Fundamentally, the company continues to struggle with profitability, posting a -46.74% net income margin and -$1.30B net loss in 2025 despite $4.37B revenue. Recent news highlights the company's mortgage expansion strategy and ongoing challenges in the housing market.

While analyst consensus suggests significant upside potential with a $4.92 price target, the company faces substantial execution risks amid persistent losses and high debt levels. The path to profitability remains uncertain, with revenue declining from $15.6B in 2022 to $4.4B in 2025. Investors should weigh the discounted valuation against ongoing operational challenges in the volatile housing sector.